Campaign for Accountability

Bradford birthplace of Brontë sisters goes up for sale

Retrieved on: 
Monday, October 16, 2023
People, Coventry UK City of Culture 2021, Architectural Heritage Fund, Hope, St. James' Church, Campaign for Accountability, Sibling, BBC Yorkshire, Branwell Brontë, The Tenant of Wildfell Hall, Anne Brontë, Bell, City, BBC, Grade, Tenant, Comment, City of Bradford Metropolitan District Council, Ownership, Clergy house, Woman, Coffeehouse, Sale, Whaling, Nursing, Department store, Culture, Market Street, Facebook

Bradford birthplace of Brontë sisters goes up for sale

Key Points: 
  • Bradford birthplace of Brontë sisters goes up for sale
    - Published
    The birthplace of the famous Brontë sisters has gone up for sale, with campaigners saying they hope to take it into community ownership.
  • Since launching on 9 October, the Brontë Birthplace Committee's appeal has already raised nearly £20,000.
  • Brontë Birthplace Committee vice-chair Steve Stanworth said: "Three world famous authors were born in this property.
  • Campaigners said the site would complement Thornton's Brontë Bell Chapel, where Patrick Brontë gave his sermons, and St James Church, where the sisters were baptised.

NTRA 4-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Natera, Inc. (NTRA) Investors with Losses to Contact Firm’s Attorneys Before June 27th Deadline in Securities Class Action

Retrieved on: 
Thursday, June 23, 2022
GLOBE, Hindenburg, SEC, Prader–Willi syndrome, Insurance, Campaign for Accountability, NASDAQ, NTRA, Accountability, The New York Times, Research, Program, Campaign, Person, Oportunidades, Steve Berman (lawyer), DiGeorge syndrome, Hindenburg Research, SAN, News, Lists of diseases, Time, Fraud, Tobacco, Pharmaceutical industry, Natera, Panorama

SAN FRANCISCO, June 23, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Natera, Inc. (NASDAQ: NTRA) investors who suffered significant losses and wish to lead the securities fraud case to submit your losses now .

Key Points: 
  • SAN FRANCISCO, June 23, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Natera, Inc. (NASDAQ: NTRA) investors who suffered significant losses and wish to lead the securities fraud case to submit your losses now .
  • On Jan. 14, 2022, the Campaign for Accountability requested the SEC to investigate whether Natera knowingly overstated the accuracy of Panorama.
  • Were focused on investors losses and proving Natera misrepresented the reliability and superiority of its tests, said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • Hagens Berman is a global plaintiffs rights complex litigation law firm focusing on corporate accountability through class-action law.

NTRA 10-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Natera, Inc. (NTRA) Investors with Losses to Contact Firm’s Attorneys, Deadline Approaching in Securities Class Action

Retrieved on: 
Friday, June 17, 2022
Hindenburg Research, Time, DiGeorge syndrome, Fraud, Research, Lists of diseases, Insurance, Person, Prader–Willi syndrome, The New York Times, GLOBE, Program, NASDAQ, News, SEC, Oportunidades, Hindenburg, Campaign, Steve Berman (lawyer), NTRA, Campaign for Accountability, SAN, Accountability, Tobacco, Pharmaceutical industry, Natera, Panorama

SAN FRANCISCO, June 17, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Natera, Inc. (NASDAQ: NTRA) investors who suffered significant losses and wish to lead the securities fraud case to submit your losses now .

Key Points: 
  • SAN FRANCISCO, June 17, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Natera, Inc. (NASDAQ: NTRA) investors who suffered significant losses and wish to lead the securities fraud case to submit your losses now .
  • On Jan. 14, 2022, the Campaign for Accountability requested the SEC to investigate whether Natera knowingly overstated the accuracy of Panorama.
  • Were focused on investors losses and proving Natera misrepresented the reliability and superiority of its tests, said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • Hagens Berman is a global plaintiffs rights complex litigation law firm focusing on corporate accountability through class-action law.

Hagens Berman, National Trial Attorneys, Encourages Natera, Inc. (NTRA) Investors with Losses to Contact Firm’s Attorneys, Deadline Approaching in Securities Class Action

Retrieved on: 
Tuesday, May 31, 2022
Hindenburg, Oportunidades, Prader–Willi syndrome, Fraud, Steve Berman (lawyer), Research, DiGeorge syndrome, Person, News, Insurance, NASDAQ, Accountability, Campaign, NTRA, SAN, Time, Campaign for Accountability, Program, Lists of diseases, SEC, Hindenburg Research, The New York Times, GLOBE, Tobacco, Pharmaceutical industry, Panorama, Natera

On Jan. 14, 2022, the Campaign for Accountability requested the SEC to investigate whether Natera knowingly overstated the accuracy of Panorama.

Key Points: 
  • On Jan. 14, 2022, the Campaign for Accountability requested the SEC to investigate whether Natera knowingly overstated the accuracy of Panorama.
  • Were focused on investors losses and proving Natera misrepresented the reliability and superiority of its tests, said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • If you invested in Natera and have significant losses, or have knowledge that may assist the firms investigation, click here to discuss your legal rights with Hagens Berman .
  • Hagens Berman is a global plaintiffs rights complex litigation law firm focusing on corporate accountability through class-action law.

NTRA INVESTOR DEADLINE: Hagens Berman, National Trial Attorneys, Encourages Natera, Inc. (NTRA) Investors with Losses to Contact Firm’s Attorneys, Securities Class Action Pending

Retrieved on: 
Monday, May 23, 2022
Hindenburg, Oportunidades, Prader–Willi syndrome, Fraud, Steve Berman (lawyer), Research, DiGeorge syndrome, Person, News, Insurance, NASDAQ, Accountability, Campaign, NTRA, SAN, Time, Campaign for Accountability, Program, Lists of diseases, SEC, Hindenburg Research, The New York Times, GLOBE, Tobacco, Pharmaceutical industry, Panorama, Natera

SAN FRANCISCO, May 23, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Natera, Inc. (NASDAQ: NTRA) investors who suffered significant losses and wish to lead the securities fraud case to submit your losses now .

Key Points: 
  • SAN FRANCISCO, May 23, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Natera, Inc. (NASDAQ: NTRA) investors who suffered significant losses and wish to lead the securities fraud case to submit your losses now .
  • On Jan. 14, 2022, the Campaign for Accountability requested the SEC to investigate whether Natera knowingly overstated the accuracy of Panorama.
  • Were focused on investors losses and proving Natera misrepresented the reliability and superiority of its tests, said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • Hagens Berman is a global plaintiffs rights complex litigation law firm focusing on corporate accountability through class-action law.

Natera, Inc. Investor News: Robbins LLP Is Investigating Natera, Inc. (NTRA) on Behalf of Shareholders

Retrieved on: 
Friday, May 20, 2022
Legal, Professional Services, Steps, Oportunidades, Company, News, Patient, Genetic testing, Insurance, NASDAQ, Accountability, Health, Campaign, NTRA, Marketing, FDA, NIPT, Panorama, Time, Campaign for Accountability, Complaint, Communication, Technology, Safety, Lists of diseases, SEC, Hindenburg Research, The New York Times, Pharmaceutical industry, Natera

Natera offers genetic testing in the area of women's health, oncology, and organ health.

Key Points: 
  • Natera offers genetic testing in the area of women's health, oncology, and organ health.
  • If you would like more information about our investigation of Natera Inc.'s misconduct, click here .
  • What is this Case About: According to a complaint filed against Natera, Natera produces and markets a non-invasive prenatal test [NIPT] called "Panorama," and a screening test for kidney transplant failure called "Prospera."
  • On this news, Natera stock fell almost 4% to close at $38.10 per share on April 20, 2022.

NTRA CLASS ACTION: Hagens Berman, National Trial Attorneys, Encourages Natera, Inc. (NTRA) Investors with Losses to Contact Firm’s Attorneys, Securities Fraud Class Action Filed

Retrieved on: 
Monday, May 9, 2022
Hindenburg, Steve Berman (lawyer), Prader–Willi syndrome, Insurance, NASDAQ, GLOBE, The New York Times, Research, Time, Fraud, DiGeorge syndrome, Program, Campaign, NTRA, Oportunidades, Campaign for Accountability, Hindenburg Research, Lists of diseases, SEC, News, SAN, Accountability, Person, Tobacco, Pharmaceutical industry, Panorama, Natera

SAN FRANCISCO, May 09, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Natera, Inc. (NASDAQ: NTRA) investors who suffered significant losses and wish to lead the securities fraud case to submit your losses now .

Key Points: 
  • SAN FRANCISCO, May 09, 2022 (GLOBE NEWSWIRE) -- Hagens Berman urges Natera, Inc. (NASDAQ: NTRA) investors who suffered significant losses and wish to lead the securities fraud case to submit your losses now .
  • Natera, Inc. (NASDAQ: NTRA) Securities Fraud Class Action:
    Defendants have repeatedly claimed that its screening test for kidney transplant failure (Prospera) was superior to competitors tests and that its non-invasive prenatal test (Panorama) was reliable.
  • On Jan. 14, 2022, the Campaign for Accountability requested the SEC to investigate whether Natera knowingly overstated the accuracy of Panorama.
  • Were focused on investors losses and proving Natera misrepresented the reliability and superiority of its tests, said Reed Kathrein, the Hagens Berman partner leading the investigation.

Natera, Inc. Stock News: Contact Robbins LLP to Learn More About Your Rights Against Natera, Inc. (NTRA)

Retrieved on: 
Thursday, May 5, 2022
Steps, Genetic testing, Communication, Insurance, NIPT, NASDAQ, GLOBE, The New York Times, Securities Exchange Act of 1934, Safety, Time, Patient, FDA, Person, Campaign, NTRA, Oportunidades, Panorama, Campaign for Accountability, Health, Reliability, Marketing, Hindenburg Research, Lists of diseases, SEC, Technology, News, SAN, Accountability, Accuracy and precision, Pharmaceutical industry, Natera

Natera offers genetic testing in the area of women's health, oncology, and organ health.

Key Points: 
  • Natera offers genetic testing in the area of women's health, oncology, and organ health.
  • However, as investors began to learn the truth, the stock price spiraled downwards.
  • On this news, Natera stock fell almost 4% to close at $38.10 per share on April 20, 2022.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

NTRA INVESTORS: June 27, 2022 Filing Deadline in Securities Class Action – Contact Lieff Cabraser

Retrieved on: 
Thursday, May 5, 2022
Legal, Professional Services, Benchmark, Genetic testing, Fetus, Insurance, U.S. Securities and Exchange Commission, Nasdaq, National Institute for Pharmaceutical Technology & Education (NIPTE), Pregnancy, The New York Times, Company, The National Law Journal, Food, Chromosome, Time, Patient, FDA, Campaign, NTRA, Court, Panorama, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Campaign for Accountability, Lists of schools in England, LLP, Hindenburg Research, Lists of diseases, News, Accountability, Awareness, NIPT, Tobacco, Pharmaceutical industry, Online gambling, Oportunidades, Natera

A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.

Key Points: 
  • A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.
  • Your share of any recovery in the actions will not be affected by your decision of whether to seek appointment as lead plaintiff.
  • You may retain Lieff Cabraser, or other attorneys, as your counsel in the action.
  • The National Law Journal has recognized Lieff Cabraser as one of the nations top plaintiffs law firms for fourteen years.

Natera, Inc. Shareholder Update: Robbins LLP Reminds Investors of Class Action Against Natera, Inc. (NTRA)

Retrieved on: 
Tuesday, May 3, 2022
Legal, Professional Services, Steps, Genetic testing, Communication, Insurance, NIPT, The New York Times, Securities Exchange Act of 1934, NYSE, Safety, Time, Patient, FDA, Person, Campaign, NTRA, Oportunidades, Panorama, Campaign for Accountability, Health, Reliability, Marketing, Hindenburg Research, Lists of diseases, SEC, Technology, News, Accountability, Accuracy and precision, Pharmaceutical industry, Natera

The Class: Shareholder rights law firm Robbins LLP reminds investors of a class action on behalf of all persons and entities that purchased or otherwise acquired Natera, Inc. (NYSE: NTRA) securities between February 26, 2020 and April 19, 2022, for violations of the Securities Exchange Act of 1934.

Key Points: 
  • The Class: Shareholder rights law firm Robbins LLP reminds investors of a class action on behalf of all persons and entities that purchased or otherwise acquired Natera, Inc. (NYSE: NTRA) securities between February 26, 2020 and April 19, 2022, for violations of the Securities Exchange Act of 1934.
  • During the class period, defendants assured investors Panorama was reliable, that Prospera was more accurate than competing tests, and that Natera's growth was driven by its superior technology and customer experience.
  • On this news, Natera stock fell almost 4% to close at $38.10 per share on April 20, 2022.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.